A Decade Later: 5 Unfamiliar Rule Breakers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Should l Buy ISRG?
Source: NASDAQ.COM
Overview of the Five Stock Sampler: The podcast revisits a five-stock sampler from November 11, 2015, featuring lesser-known companies, including Middleby, MicroStrategy, NetSuite, NuVasive, and Trex, to evaluate their performance over the past decade against the S&P 500.
Performance Analysis: The overall performance of the five stocks resulted in a 304.4% gain, significantly outperforming the S&P 500's average return of 183.5%, with MicroStrategy being the standout performer, increasing by 1,249%.
Individual Stock Insights: Each stock's journey was discussed, highlighting challenges and changes, such as Middleby's stagnant growth, NetSuite's acquisition by Oracle, NuVasive's buyout by Globus Medical, and Trex's volatility due to economic factors.
Future Considerations: The discussion emphasized the importance of long-term investing, the potential of Bitcoin as a significant asset, and the evolving nature of companies, suggesting that even lesser-known stocks can yield substantial returns over time.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 469.210
Low
575.00
Averages
637.32
High
740.00
Current: 469.210
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical Set to Announce Q1 Earnings on April 21
- Earnings Expectations: Intuitive Surgical is set to announce its Q1 earnings on April 21, with analysts forecasting an EPS of $2.11, reflecting a 16.6% year-over-year increase, and revenue of $2.62 billion, up 16.4%, indicating sustained profitability and growth potential.
- Historical Performance: Over the past two years, Intuitive Surgical has exceeded EPS and revenue estimates 100% of the time, showcasing its financial stability and market confidence.
- Valuation Challenges: Despite strong fundamentals, Seeking Alpha's Quant model rates Intuitive Surgical as a Hold due to its high P/E ratio of 63 compared to a historical average of 53.5, highlighting investment risks associated with elevated valuations.
- Market Leadership: As the leader in robotic-assisted surgery, Intuitive Surgical reported an 18% increase in procedures and a 19% revenue growth to $2.87 billion in Q4, with robust cash flow and high margins providing a solid foundation for future growth despite recent technical weaknesses.
See More
Intuitive Surgical Continues Robust Growth
- Market Value Insight: Intuitive Surgical boasts a market value nearing $163 billion, and while its shares are currently priced below average, it maintains a dominant position in the robotic surgical systems sector, indicating strong market presence and future growth potential.
- Investment Return Outlook: Investing $1,000 monthly with an assumed annual growth rate of 12% could yield $864,629 after 20 years, suggesting the company has the potential to provide substantial retirement income for investors, especially if it begins paying dividends in the future.
- Valuation Metrics: The current forward P/E ratio stands at 46, which, although high, is lower than the five-year average of 57, indicating relative investment attractiveness, while the price-to-sales ratio of 16.5 is also below the five-year average of 18.4.
- Long-Term Holding Recommendation: Despite potential short-term price fluctuations, purchasing Intuitive Surgical shares now could yield favorable returns for long-term investors, with a strategy of gradually building a position to mitigate risk.
See More
Intuitive Surgical to Release Q1 Earnings on April 21
- Earnings Release Announcement: Intuitive Surgical is set to release its Q1 2023 earnings on April 21, with analysts forecasting an EPS of $2.11 and revenue of $2.62 billion, indicating the company's ongoing growth potential in the medical device sector.
- Market Expectation Analysis: Analysts maintain an optimistic outlook for Intuitive Surgical's earnings report, anticipating revenue growth compared to the previous year, which reflects strong demand and an increase in market share within the robotic surgery market.
- FDA Alert Impact: The FDA has issued an alert regarding stapling devices, which may negatively affect sales of related products from Intuitive Surgical in the short term, necessitating close monitoring of market reactions and the company's response strategies.
- Industry Dynamics Monitoring: As the earnings release approaches, investors should keep an eye on the overall performance of the medical device industry and regulatory developments to assess Intuitive Surgical's future growth prospects and competitive positioning.
See More
American Airlines Rejects United Airlines Merger Proposal as Anti-Competitive
- Merger Proposal Rejected: American Airlines shares fell in pre-market trading on Monday after firmly rejecting United Airlines' merger proposal, citing significant antitrust hurdles that would give the combined entity a 40% domestic market share, negatively impacting competition.
- Regulatory Scrutiny Pressure: Legal experts suggest that a merger would face unprecedented scrutiny, as the 'Big Four' airlines already control 80% of U.S. capacity, potentially dominating key hubs like Chicago and Dallas by up to 70%.
- Strategic Shift Possible: Despite the rejection, United Airlines may pivot towards smaller acquisitions or asset divestitures to satisfy an administration favoring landmark deals while avoiding concerns over consumer pricing monopolies, thereby maintaining competitive positioning.
- Market Reaction: Following the merger proposal rejection, American Airlines' stock dropped 3.13% and United Airlines' stock fell 3.04%, reflecting market pessimism regarding the merger prospects and potentially influencing future strategic decisions for both companies.
See More
Tesla Set to Report Q1 Earnings Amid Market Surge
- Tesla Earnings Outlook: Tesla is set to report its Q1 fiscal 2026 earnings on Wednesday, with the stock down 11% year-to-date; however, it has shown recovery in April as CEO Elon Musk garners attention for the upcoming SpaceX IPO, and analysts predict profit growth despite vehicle deliveries of 358,000 falling short of the 370,000 expected.
- Terafab Project Acceleration: Musk is urging potential suppliers to expedite the Terafab AI chip-making project, which is estimated to cost over $25 billion and aims to achieve an annual computing capacity of one terawatt, highlighting Tesla's ambitions in the AI sector.
- Market Performance Surge: Despite uncertainties surrounding dealings with Iran, both the S&P 500 and Nasdaq reached new all-time highs, rising 4.5% and 6.8% respectively, while the Dow Jones increased by 3.2%, indicating a robust market recovery.
- Oil Price Impact: Following the U.S. Navy's seizure of an Iranian-flagged ship, benchmark crude prices surged over 6%, with West Texas Intermediate surpassing $88 and Brent crude exceeding $95, which could influence market sentiment.
See More
Intuitive Surgical: Future Investment Potential
- Market Value Growth: Intuitive Surgical boasts a market value nearing $163 billion, and while it currently does not pay dividends, its share repurchases enhance shareholder value, demonstrating a commitment to returns.
- Global Impact: Over 20.4 million patients have undergone procedures with Intuitive systems, which are utilized in more than 70 countries, with over 12,000 systems installed, underscoring its leadership in the robotic surgery sector.
- Strong Financial Performance: The company's latest earnings report revealed a 19% year-over-year revenue increase to $2.9 billion, with procedures growing by 18%, and Ion system procedures surging by 44%, indicating robust product demand.
- Investment Outlook Analysis: Despite a current P/E ratio of 46, below the five-year average of 57, if investors contribute $1,000 monthly with an assumed 12% annual growth, they could accumulate $864,629 in 20 years, highlighting the potential of long-term investments.
See More
Intuitive Surgical Set to Announce Q1 Earnings on April 21
- Earnings Expectations: Intuitive Surgical is set to announce its Q1 earnings on April 21, with analysts forecasting an EPS of $2.11, reflecting a 16.6% year-over-year increase, and revenue of $2.62 billion, up 16.4%, indicating sustained profitability and growth potential.
- Historical Performance: Over the past two years, Intuitive Surgical has exceeded EPS and revenue estimates 100% of the time, showcasing its financial stability and market confidence.
- Valuation Challenges: Despite strong fundamentals, Seeking Alpha's Quant model rates Intuitive Surgical as a Hold due to its high P/E ratio of 63 compared to a historical average of 53.5, highlighting investment risks associated with elevated valuations.
- Market Leadership: As the leader in robotic-assisted surgery, Intuitive Surgical reported an 18% increase in procedures and a 19% revenue growth to $2.87 billion in Q4, with robust cash flow and high margins providing a solid foundation for future growth despite recent technical weaknesses.
See More
Intuitive Surgical Continues Robust Growth
- Market Value Insight: Intuitive Surgical boasts a market value nearing $163 billion, and while its shares are currently priced below average, it maintains a dominant position in the robotic surgical systems sector, indicating strong market presence and future growth potential.
- Investment Return Outlook: Investing $1,000 monthly with an assumed annual growth rate of 12% could yield $864,629 after 20 years, suggesting the company has the potential to provide substantial retirement income for investors, especially if it begins paying dividends in the future.
- Valuation Metrics: The current forward P/E ratio stands at 46, which, although high, is lower than the five-year average of 57, indicating relative investment attractiveness, while the price-to-sales ratio of 16.5 is also below the five-year average of 18.4.
- Long-Term Holding Recommendation: Despite potential short-term price fluctuations, purchasing Intuitive Surgical shares now could yield favorable returns for long-term investors, with a strategy of gradually building a position to mitigate risk.
See More
Intuitive Surgical to Release Q1 Earnings on April 21
- Earnings Release Announcement: Intuitive Surgical is set to release its Q1 2023 earnings on April 21, with analysts forecasting an EPS of $2.11 and revenue of $2.62 billion, indicating the company's ongoing growth potential in the medical device sector.
- Market Expectation Analysis: Analysts maintain an optimistic outlook for Intuitive Surgical's earnings report, anticipating revenue growth compared to the previous year, which reflects strong demand and an increase in market share within the robotic surgery market.
- FDA Alert Impact: The FDA has issued an alert regarding stapling devices, which may negatively affect sales of related products from Intuitive Surgical in the short term, necessitating close monitoring of market reactions and the company's response strategies.
- Industry Dynamics Monitoring: As the earnings release approaches, investors should keep an eye on the overall performance of the medical device industry and regulatory developments to assess Intuitive Surgical's future growth prospects and competitive positioning.
See More
American Airlines Rejects United Airlines Merger Proposal as Anti-Competitive
- Merger Proposal Rejected: American Airlines shares fell in pre-market trading on Monday after firmly rejecting United Airlines' merger proposal, citing significant antitrust hurdles that would give the combined entity a 40% domestic market share, negatively impacting competition.
- Regulatory Scrutiny Pressure: Legal experts suggest that a merger would face unprecedented scrutiny, as the 'Big Four' airlines already control 80% of U.S. capacity, potentially dominating key hubs like Chicago and Dallas by up to 70%.
- Strategic Shift Possible: Despite the rejection, United Airlines may pivot towards smaller acquisitions or asset divestitures to satisfy an administration favoring landmark deals while avoiding concerns over consumer pricing monopolies, thereby maintaining competitive positioning.
- Market Reaction: Following the merger proposal rejection, American Airlines' stock dropped 3.13% and United Airlines' stock fell 3.04%, reflecting market pessimism regarding the merger prospects and potentially influencing future strategic decisions for both companies.
See More
Tesla Set to Report Q1 Earnings Amid Market Surge
- Tesla Earnings Outlook: Tesla is set to report its Q1 fiscal 2026 earnings on Wednesday, with the stock down 11% year-to-date; however, it has shown recovery in April as CEO Elon Musk garners attention for the upcoming SpaceX IPO, and analysts predict profit growth despite vehicle deliveries of 358,000 falling short of the 370,000 expected.
- Terafab Project Acceleration: Musk is urging potential suppliers to expedite the Terafab AI chip-making project, which is estimated to cost over $25 billion and aims to achieve an annual computing capacity of one terawatt, highlighting Tesla's ambitions in the AI sector.
- Market Performance Surge: Despite uncertainties surrounding dealings with Iran, both the S&P 500 and Nasdaq reached new all-time highs, rising 4.5% and 6.8% respectively, while the Dow Jones increased by 3.2%, indicating a robust market recovery.
- Oil Price Impact: Following the U.S. Navy's seizure of an Iranian-flagged ship, benchmark crude prices surged over 6%, with West Texas Intermediate surpassing $88 and Brent crude exceeding $95, which could influence market sentiment.
See More
Intuitive Surgical: Future Investment Potential
- Market Value Growth: Intuitive Surgical boasts a market value nearing $163 billion, and while it currently does not pay dividends, its share repurchases enhance shareholder value, demonstrating a commitment to returns.
- Global Impact: Over 20.4 million patients have undergone procedures with Intuitive systems, which are utilized in more than 70 countries, with over 12,000 systems installed, underscoring its leadership in the robotic surgery sector.
- Strong Financial Performance: The company's latest earnings report revealed a 19% year-over-year revenue increase to $2.9 billion, with procedures growing by 18%, and Ion system procedures surging by 44%, indicating robust product demand.
- Investment Outlook Analysis: Despite a current P/E ratio of 46, below the five-year average of 57, if investors contribute $1,000 monthly with an assumed 12% annual growth, they could accumulate $864,629 in 20 years, highlighting the potential of long-term investments.
See More
